Application of parallel multiparametric cell-based FLIPR detection assays for the identification of modulators of the muscarinic acetylcholine receptor 4 (M4)

Journal of Biomolecular Screening

Volumn 20, Issue 7, 2015, Pages 858-868

  Smith, Emery ^a   Chase, Peter ^a   Niswender, Colleen M ^b   Utley, Thomas J ^b   Sheffler, Douglas J ^b,c   Noetzel, Meredith J ^b   Lamsal, Atin ^b   Wood, Michael R ^b   Conn, P Jeffrey ^b   Lindsley, Craig W ^b   Madoux, Franck ^a   Acosta, Mary ^a   Scampavia, Louis ^a   Spicer, Timothy ^a   Hodder, Peter ^a,d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d AMGEN INC   (United States)

Author keywords

GPCR; muscarinic; parallel screening; positive allosteric modulators

Indexed keywords

MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M4 RECEPTOR MODULATOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; MOLECULAR LIBRARY;

ALLOSTERISM; ALZHEIMER DISEASE; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; ARTIFACT; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG SELECTIVITY; FLUORESCENT IMAGING PLATE READER ASSAY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL LINE; CHEMISTRY; DRUG DEVELOPMENT; GENE EXPRESSION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOLECULAR LIBRARY; PROCEDURES;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE; DRUG DISCOVERY; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M4; SMALL MOLECULE LIBRARIES;

EID: 84937885798     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115581770     Document Type: Article

References (28)

1. George S. R., O'Dowd B. F., Lee S. P., G-Protein-Coupled Receptor Oligomerization and Its Potential for Drug Discovery. Nat. Rev. Drug Discov. 2002, 1, 808-820.
2. Rana B. K., Shiina T., Insel P. A., Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 593-624.
3. Howard A. D., McAllister G., Feighner S. D.,. Orphan G-Protein-Coupled Receptors and Natural Ligand Discovery. Trends Pharmacol. Sci. 2001, 22, 132-140.
4. Jeffrey Conn P., Christopoulos A., Lindsley C. W., Allosteric Modulators of GPCRs: A Novel Approach for the Treatment of CNS Disorders. Nat. Rev. Drug Discov. 2009, 8, 41-54.
5. Conn P. J., Lindsley C. W., Jones C. K., Activation of Metabotropic Glutamate Receptors as a Novel Approach for the Treatment of Schizophrenia. Trends Pharmacol. Sci. 2009, 30, 25-31.
6. Ishii M., Kurachi Y., Muscarinic Acetylcholine Receptors. Curr. Pharmaceut. Des. 2006, 12, 3573-3581.
7. Langmead C. J., Watson J., Reavill C., Muscarinic Acetylcholine Receptors as CNS Drug Targets. Pharmacol. Ther. 2008, 117, 232-243.
8. Katzenschlager R., Sampaio C., Costa J., Lees A., Anticholinergics for Symptomatic Management of Parkinson's Disease. Cochrane Database Sys. Rev. 2002, 3, CD003735.
9. Gentry P. R., Kokubo M., Bridges T. M.,. Discovery, Synthesis and Characterization of a Highly Muscarinic Acetylcholine Receptor (mAChR)-Selective M5-Orthosteric Antagonist, VU0488130 (ML381): A Novel Molecular Probe. ChemMedChem. 2014, 9, 1677-1682.
10. Heyse S., Bruttger O., Duerr O.,. Quantifying Bioactivity on a Large Scale: Quality Assurance and Analysis of Multiparametric Ultra-HTS Data. J. La. Automat. 2005, 10, 207-212.
11. Lewis L. M., Bridges T. M., Niswender C. M.,. Discovery of a Highly Selective In Vitro and In Vivo M4 Positive Allosteric Modulator (PAM). In Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information, Bethesda, MD, 2010.
12. Conklin B. R., Farfel Z., Lustig K. D.,. Substitution of Three Amino Acids Switches Receptor Specificity of Gq Alpha to That of Gi Alpha. Nature 1993, 363, 274-276.
13. Zhang J. H., Chung T., Oldenburg K., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
14. Spicer T., Fernandez-Vega V., Chase P.,. Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening. J. Biomol. Screen. 2014, 19, 1107-1115.
15. Burford N. T., Wehrman T., Bassoni D.,. Identification of Selective Agonists and Positive Allosteric Modulators for Micro- and Delta-Opioid Receptors from a Single High-Throughput Screen. J. Biomol. Screen. 2014, 19, 1255-1265.
16. Liu K., Southall N., Titus S.,. A Multiplex Calcium Assay for Identification of GPCR Agonists and Antagonists. Assay Drug Dev. Technol. 2010, 8, 367-369.
17. Jacoby E., Bouhelal R., Gerspacher M.,. The 7 TM G-Protein-Coupled Receptor Target Family. ChemMedChem. 2006, 1, 761-782.
18. Rodriguez A. L., Grier M. D., Jones C. K.,. Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity. Mol. Pharmacol. 2010, 78, 1105-1123.
19. Noblin D. J., Bertekap R. L. Jr., Burford N. T.,. Development of a High-Throughput Calcium Flux Assay for Identification of All Ligand Types Including Positive, Negative, and Silent Allosteric Modulators for G Protein-Coupled Receptors. Assay Drug Dev. Technol. 2012, 10, 457-467.
20. Brothers S. P., Saldanha S. A., Spicer T. P.,. Selective and Brain Penetrant Neuropeptide y y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening. Mol. Pharmacol. 2010, 77, 46-57.
21. Hodder P., Cassaday J., Peltier R.,. Identification of Metabotropic Glutamate Receptor Antagonists Using an Automated High-Throughput Screening System. Anal. Biochem. 2003, 313, 246-254.
22. Noetzel M. J., Rook J. M., Vinson P. N.,. Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function. Mol. Pharmacol. 2012, 81, 120-133.
23. Conn P. J., Jones C. K., Lindsley C. W., Subtype-Selective Allosteric Modulators of Muscarinic Receptors for the Treatment of CNS Disorders. Trends Pharmacol. Sci. 2009, 30, 148-155.
24. Han C., Chatterjee A., Noetzel M. J.,. Discovery and SAR of Muscarinic Receptor Subtype 1 (M) Allosteric Activators from a Molecular Libraries High Throughput Screen. Part 1: 2,5-Dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as Positive Allosteric Modulators. Bioorg. Med. Chem. Lett. 2015, 25, 384-388.
25. Niswender C. M., Johnson K. A., Luo Q.,. A Novel Assay of Gi/o-Linked G Protein-Coupled Receptor Coupling to Potassium Channels Provides New Insights into the Pharmacology of the Group III Metabotropic Glutamate Receptors. Mol. Pharmacol. 2008, 73, 1213-1224.
26. Gentry P. R., Discovery, Optimization, and Characterization of Novel Subtype-Selective M5 Muscarinic Acetylcholine Receptor Ligands; Ph.D. Thesis, Vanderbilt University, 2014.
27. Reid P. R., Bridges T. M., Sheffler D. J.,. Discovery and Optimization of a Novel, Selective and Brain Penetrant M1 Positive Allosteric Modulator (PAM): The Development of ML169, an MLPCN Probe. Bioorg. Med. Chem. Lett. 2011, 21, 2697-2701.
28. Gentry P. R., Kokubo M., Bridges T. M.,. Discovery, Synthesis and Characterization of a Highly Muscarinic Acetylcholine Receptor (mAChR)-Selective M5-Orthosteric Antagonist, VU0488130 (ML381): A Novel Molecular Probe. ChemMedChem. 2014, 9, 1677-1682.